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Abstract
Aetiogenesis of cancer has not been fully determined. Recent advances have clearly defined a role for
microenvironmental factors in cancer progression and initiation; in this context, microbiome has recently emerged
with a number of reported correlative and causative links implicating alterations of commensal microbes in
tumorigenesis. Bacteria appear to have the potential to directly alter physiological pathways of host cells and in
specific circumstances, such as the mutation of the tumour suppressive factor p53, they can also directly switch the
function of a gene from oncosuppressive to oncogenic. In this minireview, we report a number of examples on
how commensal microbes alter the host cell biology, affecting the oncogenic process. We then discuss more in
detail how interaction with the gut microbiome can affect the function of p53 mutant in the intestinal
tumorigenesis.
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Background
In addition to the genetic factors [1], microenviron-
mental components certainly influence cancer progres-
sion and initiation, as clear evidence emerged on the
contribution of integration of extrinsic and intrinsic
factors in the disease pathogenesis [2, 3]. Genomic
studies have clarified the genetic basis for several malig-
nancies [4–6], as for examples neuroblastoma, which
shows a clear pattern of mutations with a well-defined
prognostic value [7–11]. In a wider perspective, how-
ever, distal interaction among different organs can also
contribute to pathogenesis of cancer. The gut micro-
biota has emerged as determinants not only for the
health of gastrointestinal tract (GI), but also for distal
districts such as brain, pancreas and liver [12–15].
Causative links between dysbiosis and neurodegenera-
tion, diabetic, obesity and cancer have been postulated
and in part also demonstrated [16–19].
Colorectal cancer (CRC) is directly linked to gut micro-
biota. CRC-enriched bacteria have been identified with faecal
metagenomic approaches on patients with CRC [20, 21].
These include Parvimonas micra, Fusobacterium nucleatum,
Bacteroides fragilis, Porphyromonas asaccharolytica, Therma-
naerovibrio acidaminovorans, Prevotella intermedia and
Alistipes finegoldii [22, 23]. They may serve as diagnostic
markers of diseases; they may also direct on a better under-
standing of the CRC pathogenesis and may provide thera-
peutic strategies in the future.
An important aspect that links dysbiosis and cancer
pathogenesis is inflammation. Bacterial infection can in-
deed result in cancer. Gastric infection with Helicobacter
pylori causes persistent inflammation and gastritis,
resulting in a significant proportion of individuals in
stomach malignancies [24]. Similarly colitis can result in
tumorigenesis [25, 26, 27]. The microbiota is altered by
the colitis-associated inflammation as well as altered
microbiota might be causative of colitis. Interaction with
host and commensal bacteria seems to have crucial im-
plications on human health. There is indeed a fine
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balance between microbiota, inflammatory response and
immune system that influences tumorigenesis.
Here, we will summarise major recent advance on the
interaction between microbiota and human malignan-
cies, with a particular focus on GI conditions. We will
also discuss the potential paradoxical impact that micro-
biota can have on tumour suppressive mechanisms, such
as the recently reported effect of switching mutant p53
from tumour-suppressive to oncogenic role [28].
The microbiota in Cancer progression
Dysbiosis is generally associated to commensal microbes
outcompeted [29]; this can favour establishment of
pathogenic microbes that might have causative roles in
cancer (Fig. 1). Antibiotics can be the cause of outcom-
peting gut commensal microbiome, thus facilitating es-
tablishment of pathogenic bacteria colonies that
ultimately may lead to inflammation and in specific cir-
cumstances to cancer. A deep understanding of the con-
sequences of gut dysbiosis and the molecular basis of
these represent a priority to direct research efforts in the
area of cancer pathogenesis [30].
Several bacteria strains have been identified [31, 32] and
associated to cancer progression and in some instance,
these can produce directly or indirectly DNA damage.
Fusobacterium nucleatum has an established role in gas-
tric, pancreatic and colorectal cancers [33–35]. Interaction
between FadA adhesin protein from F. nucleatum can
interact with E-Cadherin, triggering activation of beta-
catenin signalling, which ultimately modulates inflamma-
tory and oncogenic responses to promote tumorigenesis.
CRC patients display an elevated level of FadA protein
and Wnt7b and NFkB2 mRNAs. Thus, FadA appears to
promote tumorigenesis and F. nucleatum associated in-
flammation [36]. FadA has also been implicated in the con-
trol of natural killer (NK) cell cytotoxicity via its interaction
with T cell immunoglobulin and ITIM domain (TIGIT),
producing cell death in human lymphocytes [37, 38]. Also
Citrobacter can mediate Wnt-β-catenin activation through
R-spondin 2 in infected mice, producing expansion of intes-
tinal stem cells and poor differentiation [39]. Enterotoxi-
genic Bacteroides fragilis also displays the ability to promote
tumorigenesis in CRC mouse model by stimulating exag-
gerated immune responses via T helper 17 (Th17) cells
[40]. Interaction between microbes and immune system is
therefore central in the mechanisms underlying disease on-
set and progression.
Similarly, to Fusobacterium nucleatum, also P. anaero-
bius has been associated to CRC. P. anaerobius displays
interaction ability with α2/β1 integrin expressed on co-
lonic cancer cells by its surface protein, putative cell wall
binding repeat 2 (PCWBR2). Interaction occurs on the
CRC cells, but not with the normal colonic epithelial
cells. α2/β1 integrin in turn activates PI3K-Akt pathway,
which promotes cell proliferation, as well as inflamma-
tion via nuclear factor kappa-light-chain-enhancer of ac-
tivated B cells (NF-κB), recruiting in the tumour
microenvironment the tumour-infiltrating MDSCs and
TAMs [41]. P. anaerobius can also interact with toll-like
receptor 2 (TLR2) and TLR4 on colon cells, and modu-
late myeloid-derived suppressor cells (MDSCs), granulo-
cytic tumour-associated neutrophils and tumour-
associated macrophages (TAMs), thus promoting CRC
[42]. In the context of this wide interplay governing the
Fig. 1 Gut microbiota symbiosis vs dysbiosis. Alterations of the fine balance within commensal bacteria colonies in the gut microbiota can affect
immune systems with a consequence release of pro-inflammatory cytokines and mediators, such as TNF-a and IFN-g. Recruitment of immune
system can lead to sustained inflammation, which has been associated to increased susceptibility to cancer. DC, Dendritic Cells; Th, T helper cells;
Marcop, Macrophages
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balance between microbes, colon epithelia and immune
system it becomes central the response to xenobiotics.
Within these, it is of particular relevance the chemother-
apy and the general responsiveness to anti-cancer ther-
apy. Hence, efforts should be directed to examining the
effect of bacterial species on chemotherapies and cancer
immunotherapies and how this interplay influence the
response to cancer therapy.
The microbiota in Cancer therapy
Prediction on how the gut microbiota may influence the
therapeutic response to anticancer agents should take into ac-
count a myriad of intrinsic and extrinsic factors and their own
interaction with each other. A large part of the altered antican-
cer therapy response is associated to the effect on the immune
system; hence this indicates that these aspects are of significant
importance for immunocheckpoint blockade therapy. How-
ever, gut microbiota has been proved to equally affect and
alter response to standard anti-cancer therapy, with mecha-
nisms that can involve or not the host immune system.
Radiotherapy represents an established curative and
palliative therapeutic protocol for different types of can-
cers. A significant part of radiotherapy efficacy is medi-
ated by potent immune modulatory effects, including
tumour-associated antigen cross-priming with antitumor
CD8+ T cell elicitation and abscopal effects. Vanco-
mycin, a gram-positive bacteria effective antibiotic, is
capable of potentiating the radiotherapy-induced im-
mune response against the tumour, thus inhibiting
tumour growth in mouse transplanted B16-OVA melan-
oma and TC-1 lung/cervical models. Mechanistically,
the effect was mediated by elicitation of cytolytic CD8+
T cells and IFN-γ response. Hence, depletion of
vancomycin-sensitive bacteria is proposed to enhance
the antitumor activity of radiotherapy [43].
Enterococcus hirae and Barnesiella intestinihominis ap-
pears involved in response to the anti-cancer immuno-
modulatory agent cyclophosphamide. In particular B.
intestinihominis shows ability to promote the infiltration
of IFN-γ-producing γδT cells in cancer lesions, while E.
hirae increases the intratumoral CD8/Treg ratio by
translocating from the small intestine to secondary
lymphoid organs. The bioactivity of these microbes as
well as the response to cyclophosphamide can be limited
by the immune sensor NOD2 [44]. Memory Th1 im-
mune cells promoted by E. hirae and B. intestinihominis
showed ability to predict longer progression-free survival
in patients treated with chemo-immunotherapy. Clos-
tridium has been proven to be an important player in
the regulation of bile acids, thus influencing chemokine
CXCL16 release. Bile acids can influence production by
liver sinusoidal endothelial cells of the CXCL16, which
recruits natural killer T (NKT) cells to the tumour, inhi-
biting primary and metastatic tumour growth [45].
Effects of microbiome on chemotherapeutic response
not associated to immunomodulation has also been
shown. The chemotherapeutic drug gemcitabine (2′,2′-
difluorodeoxycytidine), first choice for treatment of sev-
eral malignancies, including pancreatic adenocarcinoma,
can be metabolized by bacteria into its inactive form, 2′,
2′-difluorodeoxyuridine. Intratumor Gammaproteobac-
teria was able to promote gemcitabine resistance in a
mouse model of colon cancer. Consistently a significant
proportion of human PDACs (76%) were found positive
to bacteria [46]. Hence, resistance to gemcitabine treat-
ment, that currently emerges in PDAC treatment might
be associated to altered microbiome [47].
p53 mutations in cancer pathogenesis
Sporadic mutations in p53 are observed more than 50%
of all human cancers, while germline p53 mutations that
abolish its function show a high predisposition to
tumour formation in a syndrome known as Li-Fraumeni
[48]. The pattern of mutations in p53 gene is very pecu-
liar: mutations occur in the largest majority of cases as
missense, leading to expression of mutant proteins. Only
a small proportion (less than 10%) results in non-sense
(earlier stop codon) or deletion of the gene [49].
The canonical signalling promoted by p53 results in
three major biological response: growth arrest, DNA re-
pair and eventually apoptosis [50–54]. The arrest of the
cell cycle leads to a temporary arrest of the proliferation,
which prevents replication of damaged DNA and the
transfer to daughter cells. The p53-mediated cell cycle
arrest is mediated by the transcriptional activation of
p21 [55–59], which is then followed by upregulation of a
large number of pro-apoptotic genes, including Puma,
Noxa, Bad, Bax, Bak, p53AIP1, and Fas [57, 60–63]. The
promotion of DNA repair occurs in the time-frame be-
tween cell cycle arrest and apotptosis [64–68]; if DNA
repair is successful, the cell cycle resumes.
p53 neomorphic proteins [49, 69–71], associated to mu-
tations in p53 sequence, were implicated in alteration of
physiological cellular signalling, including the function of
the p53 family members, p63 [72–76] and p73 [77–81]
and other transcriptional factors, such as HIF-1 [82] in
several different cancer types [83–85]. p63 and p73 indeed
in addition to peculiar functions in epithelia [86, 87] and
brain development [88–91], respectively, share with wt
p53 tumour suppressive abilities, which might be altered
by p53 mutants [87, 92]. These mechanisms lead to the
postulation of the gain-of-function (GOF) effects of p53
mutant [69, 93–95]. Hence, mutations in p53 protein se-
quence appear to shift the tumour suppression function.
of the wild-type protein to an oncogene form in the mu-
tant [49, 94]. Experimental evidence has however often
challenged this postulation. For example, while evidence
GOF phenotypes, such as growth in vitro soft-agar assays
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and in injected nude mice, have been shown for p53
R175H and R273H introduced in p53-null cells, p53
R172H and R270H genetically engineered mouse models
did not show any alteration in survival when compared to
p53-null mice. Consistently with the central role of func-
tional (wt) p53 in the response to multiple cellular
stressors, it might be not surprising that p53 mutant pro-
teins also shift their behaviour when interacting with dif-
ferent microenvironmental conditions. Within this
microbiome represents a major “extrinsic” factor that
might influence p53 GOF; a recent work has indeed
assessed the paradoxical effect that gut microbiome exerts
on p53 mutant.
Gut microbiota: a paradoxical effect on p53
mutant
Interaction between tumour suppression mechanisms
and microenvironment is crucial for the cancer cell fate.
This is particularly relevant in the context of p53, a
tumour suppressor that largely acts a stress response
protein. A recent work has addressed the role of mutant
p53 in gut tumorigenesis and in particular in the inter-
action with the gut microbiota. Kadosh and colleagues
demonstrated that mutant p53 (R172H and R270H) ex-
erts an evident tumour-suppressive function in the prox-
imal mouse gut, exceeding the wild-type p53 tumour
suppressive abilities. Mutant p53 was shown to substan-
tially repress WNT-driven hyperproliferation, abrogating
dysplasia in CKIaΔgut mice and tumorigenesis in Apc-
Min/+ mice with a mechanism that yet is not being eluci-
dated. Conversely however, in the distal gut p53 mutant
reproduced the expected oncogenic effect. From the
mechanistic perspective, gallic acid produced by gut
microbiota conferred to p53 mutant pro-tumorigenic
function promoting malignant phenotype.
Administration of gallic acid promoted reactivation of
WNT-mediated TCF4 activation and promoter binding
that resulted in pro-tumorigenic effects in organoids and
mouse models [28] (Fig. 2).
We recently postulated that “context is everything” for
the p53 mutant GOF [96] and these recent findings
seem to further sustain the importance of the context on
this matter. The highly unexpected nature of the find-
ings, however open to a number of relevant questions.
These clearly include the mechanisms underlying the
mutant p53 tumour suppressive function, especially in
the light of the demonstrated lack of binding on the wt
p53 sites, but also more general questions on the reason
for a high selective pressure to accumulate p53 muta-
tions in such a wide range of human tumours. Overall
the intriguing observation, that gut microbiota has a
paradoxical effect on p53 mutant switching it from
tumour suppressive to oncogenic protein, highlights
even more the complexity and the importance of host-
microbiome interaction for the disease onset and
progression.
Conclusion
Advance of the genomic technologies and computational
tools in the last 20 years have significantly impacted our
understanding of the genetic factors at the basis of ma-
lignancies [97–100]; more recent applications have how-
ever opened to the importance of (micro)-environmental
factors on the pathogenesis of cancer. In this context
microbiome has emerged as a critical player in cancer
progression, not only in gut malignancies, but also more
in general in distal organ-organ interactions [101]. The
ability of microbiome to alter the signalling pathways of
host cells is remarkable, and the recent observation of
paradoxical roles in switching the function of a protein
Fig. 2 Gut microbiota switches p53 mutant from tumour suppressor to oncogene. P53 mutants (R270H and R175H) have been reported to play
tumour suppressive role in the upper GI tract, by inhibiting activation of Wnt/b-Cat signalling. In the distal intestine (Colon), where gut microbiota
is present in higher density, bacteria-released gallic acid appears to switch p53 mutants to oncogenic activity, abrogating its capability of
opposing to Wnt signalling
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from tumour suppressive to oncogenic further underlies
the potential of this multifactorial element in the patho-
genesis of cancer. On the basis of these recent advance
massive efforts should be placed in investigating the im-
pact of commensal microbiome on the human health
[102, 103]. This could be persuaded by investigating how
recurrent antibiotics treatments and/or probiotics ad-
ministration impact cancer incidence and prognosis to
better define a significant connection between cancer
and bacteria.
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